News
RICFY
11.64
NaN%
--
Kepler Capital Remains a Buy on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 03/28 04:55
Recordati Industria initiated with an Outperform at BNP Paribas
TipRanks · 03/03 09:30
Kepler Capital Sticks to Their Buy Rating for Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 02/20 03:25
Recordati reports FY2025 results
Seeking Alpha · 02/18 18:34
Recordati Industria upgraded to Equal Weight from Underweight at Barclays
TipRanks · 02/12 11:52
Recordati Industria upgraded to Buy from Hold at Kepler Cheuvreux
TipRanks · 02/04 15:07
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Seeking Alpha · 02/03 13:52
Recordati Launches Isturisa In Canada For Cushing's Disease
NASDAQ · 01/13 13:31
Weekly Report: what happened at RICFY last week (0908-0912)?
Weekly Report · 09/15/2025 10:55
Weekly Report: what happened at RICFY last week (0901-0905)?
Weekly Report · 09/08/2025 10:57
Weekly Report: what happened at RICFY last week (0825-0829)?
Weekly Report · 09/01/2025 10:53
Weekly Report: what happened at RICFY last week (0818-0822)?
Weekly Report · 08/25/2025 11:02
Weekly Report: what happened at RICFY last week (0811-0815)?
Weekly Report · 08/18/2025 10:55
Weekly Report: what happened at RICFY last week (0804-0808)?
Weekly Report · 08/11/2025 11:01
Weekly Report: what happened at RICFY last week (0728-0801)?
Weekly Report · 08/04/2025 11:03
Weekly Report: what happened at RICFY last week (0721-0725)?
Weekly Report · 07/28/2025 11:05
Weekly Report: what happened at RICFY last week (0714-0718)?
Weekly Report · 07/21/2025 10:55
Weekly Report: what happened at RICFY last week (0707-0711)?
Weekly Report · 07/14/2025 11:03
Weekly Report: what happened at RICFY last week (0630-0704)?
Weekly Report · 07/07/2025 10:56
Weekly Report: what happened at RICFY last week (0623-0627)?
Weekly Report · 06/30/2025 11:02
More
Webull provides a variety of real-time RICFY stock news. You can receive the latest news about Recordati Industria Chimica e Farmaceutica SpA through multiple platforms. This information may help you make smarter investment decisions.
About RICFY
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.